Kamada Ltd. (KMDA)
NASDAQ: KMDA · Real-Time Price · USD
9.02
+0.16 (1.75%)
At close: Mar 9, 2026, 4:00 PM EDT
8.98
-0.04 (-0.39%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Kamada Revenue
Kamada had revenue of $47.01M in the quarter ending September 30, 2025, with 12.63% growth. This brings the company's revenue in the last twelve months to $174.79M, up 10.36% year-over-year. In the year 2024, Kamada had annual revenue of $160.95M with 12.93% growth.
Revenue (ttm)
$174.79M
Revenue Growth
+10.36%
P/S Ratio
2.88
Revenue / Employee
$416,160
Employees
420
Market Cap
503.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160.95M | 18.43M | 12.93% |
| Dec 31, 2023 | 142.52M | 13.18M | 10.19% |
| Dec 31, 2022 | 129.34M | 25.70M | 24.79% |
| Dec 31, 2021 | 103.64M | -29.60M | -22.22% |
| Dec 31, 2020 | 133.25M | 6.06M | 4.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 837.32M |
| Emergent BioSolutions | 742.90M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 303.80M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
KMDA News
- 3 days ago - Ahead of Kamada (KMDA) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Nasdaq
- 2 months ago - Kamada (KMDA) Projects Strong Revenue and EBITDA Growth by 2026 - GuruFocus
- 2 months ago - Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender - GlobeNewsWire
- 3 months ago - Kamada Ltd Corporate Update Call Transcript - GuruFocus
- 3 months ago - Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook - Benzinga
- 3 months ago - Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook - Benzinga
- 3 months ago - Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript - Seeking Alpha
- 3 months ago - Kamada (KMDA) Halts Phase 3 Trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency - GuruFocus